| P2093 | author name string | Masayuki Miyazaki | |
| | Kiyofumi Yamada | |
| | Taku Nagai | |
| | Risa Araki | |
| | Tomomi Kataoka | |
| | Akiko Ota | |
| | Yasuo Kumakura | |
| | Yuki Kawarada | |
| | Hidetaka Iwamizu | |
| | Ayaka Itoh | |
| P2860 | cites work | Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study | Q33401294 |
| | Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer | Q33419263 |
| | Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis | Q33422985 |
| | Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial | Q33427216 |
| | Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review | Q34155719 |
| | The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment | Q35205223 |
| | Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcεRI. | Q35713385 |
| | Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer | Q35753809 |
| | Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients | Q36517115 |
| | Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review | Q37402263 |
| | Platinum hypersensitivity and desensitization | Q38521636 |
| | Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. | Q41090394 |
| | Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. | Q44270043 |
| | Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma | Q44557197 |
| | A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study | Q46580718 |
| | Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. | Q51658198 |
| | Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. | Q51772362 |
| | Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. | Q52123582 |
| | Hypersensitivity reactions to carboplatin | Q77548573 |
| | Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital | Q79421116 |
| | Efficacy and Toxicity of Concurrent Chemoradiotherapy with Nedaplatin and S-1 for Head and Neck Cancer | Q82616073 |
| | Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study | Q84188290 |
| | Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies | Q84233037 |
| | Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin | Q84359387 |
| P433 | issue | 3 | |
| P304 | page(s) | 593-599 | |
| P577 | publication date | 2017-01-25 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions | |
| P478 | volume | 22 | |